Blog Posts

Proposition 34: Results Too Close to Call in Controversial California 340B Ballot Measure Contest

California voters weighed-in on Proposition 34, a controversial 340B-related ballot measure in the Nov. 5 elections.
With just over half of the expected vote total counted, it’s too early to tell whether California voters will approve [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Arkansas Officials, Providers Urge Supreme Court to Deny PhRMA’s Appeal to Overturn 340B Contract Pharmacy Access Law

Attorneys for the state of Arkansas and local providers argued the Supreme Court should not take up PhRMA's appeal to overturn a state 340B law.
Arkansas state officials and providers are urging the U.S. Supreme Court not to take up a drug industry trade group’s [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Supreme Court Hears Arguments Over DSH Calculations That Could Result in More Hospitals Qualifying for 340B

The U.S. Supreme Court recently heard arguments in a case challenging a federal rule over disproportionate share hospital calculations and payments.
The U.S. Supreme Court heard arguments Tuesday on a case challenging a federal rule over disproportionate share hospital (DSH) calculations [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

State Contract Pharmacy Lawsuit Weekly Roundup: Updates in West Virginia, Missouri, Kansas

Key briefs were filed this week in state contract pharmacy litigation in West Virginia, Missouri and Kansas.
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
Industry Insights Logo

A New Era for Value-Based Care: Driving Better Outcomes Through Innovation and Patient-Centered Care

SPONSORED CONTENT

In 2021, the Centers for Medicare & Medicaid Services (CMS) Innovation Center set a bold new strategy for healthcare delivery which aims to have all or the majority of patients in

Read More »

November 5 is Finally Here: How the 2024 Elections Could Affect the 340B Program

Voters will cast ballots in Tuesday's presidential contest between Vice President Kamala Harris (D) and former President Donald Trump (R).
When voters across the U.S. cast their ballots in Tuesday’s elections, they will not just be deciding who will control [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Major GPO Sues HRSA over Restrictions on How 340B Hospitals Purchase Initial Drug Inventory

Premier, a major GPO, has sued HRSA over a policy restricting how hospitals can purchase initial physical drug inventory.
A major group purchasing organization (GPO) is suing the federal government over a policy that it claims unlawfully restricts how [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Lilly Backs Sanofi Lawsuit Seeking HRSA 340B Records, Argues Contract Pharmacy Agreements Violate 340B Statute

Eli Lilly has filed an amicus brief in support of Sanofi's lawsuit seeking 340B contract pharmacy agreements from HRSA.
Eli Lilly is backing Sanofi’s lawsuit to compel the federal government to release all 340B contract pharmacy agreements, arguing that [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

BI Tightens Contract Pharmacy Restrictions for All Covered Entities

Boehringer Ingelheim recently announced it will tighten its 340B contract pharmacy restrictions by requiring claims data submission.
Drugmaker Boehringer Ingelheim (BI) will begin requiring all 340B covered entities to submit claims data to continue accessing 340B drugs [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Eli Lilly Announces Refunds for 340B Overcharges

Eli Lilly announced that it will refund 340B covered entities that purchased certain medications following adjustments to their ceiling prices.
Eli Lilly announced that it will refund 340B covered entities that purchased certain medications following adjustments to their ceiling prices. [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live